RECTAL CANCER, ADENOCARCINOMA
Clinical trials for RECTAL CANCER, ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECTAL CANCER, ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECTAL CANCER, ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy may let some rectal cancer patients avoid surgery
Disease control Recruiting nowThis study tests a new treatment plan for people with high-risk rectal cancer that hasn't spread. Patients get a short course of radiation, then a mix of chemotherapy and immunotherapy before considering surgery. If the cancer disappears completely, patients may choose a 'watch a…
Matched conditions: RECTAL CANCER, ADENOCARCINOMA
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Gut bacteria boost? new trial combines probiotic with cancer therapy for rectal tumors
Disease control Recruiting nowThis phase 2 trial is testing whether adding a probiotic called Probio-M9 to standard chemoradiation and an immunotherapy drug (tislelizumab) can improve outcomes for people with locally advanced rectal cancer. About 50 participants will be randomly assigned to receive either the…
Matched conditions: RECTAL CANCER, ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Seventh Medical Center of PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for advanced colorectal cancer: drug cocktail shows promise
Disease control Recruiting nowThis study tests a combination of three drugs (trastuzumab-deruxtecan, capecitabine, and bevacizumab) as a first treatment for people with HER-2 positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see how well the drugs shrink tumors. About …
Matched conditions: RECTAL CANCER, ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC